AstraZeneca PLC (AZN)


NYSE - NYSE Real Time Price. Currency in USD
33.61+0.06 (+0.18%)
At close: 4:02 PM EDT

33.61 0.00 (0.00%)
After hours: 6:09 PM EDT

People also watch:
GSKNVSSNYLLYBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open33.05
Prev Close33.55
Bid33.60 x 10300
Ask33.61 x 2400
Day's Range32.98 - 33.63
52wk Range26.97 - 35.04
1y Target EstN/A
Market Cap83.88B
P/E Ratio (ttm)38.41
Beta0.58
Volume3,505,319
Avg Vol (3m)6,026,818
Dividend & Yield0.90 (2.65%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals3 hours ago

    Big Pharma takes big lease in South S.F. to consolidate California operations

    Drug developer AstraZeneca PLC will bring more than 350 California employees together in the massive Cove at Oyster Point development in South San Francisco, the company said Tuesday. It comes as Big Pharma players, including Merck & Co. Inc., scout local sites in an effort to cozy up to hot, young Bay Area drug developers . The Cove, now in the second phase of construction by HCP Inc. at Highway 101 and Oyster Point Boulevard, already has landed high-profile biotech startups, such as neurodegenerative drug developer Denali Therapeutics Inc. and cancer drug maker CytomX Therapeutics Inc. But AstraZeneca (AZN) could dwarf those companies with its expected fourth-quarter 2017 move-in.

  • TheStreet.com12 hours ago

    Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

    A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.

  • Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema
    Investor's Business Dailyyesterday

    Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema

    The FDA could approve a breakthrough adult eczema treatment from Regeneron and Sanofi as soon as March.